Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2016 · 10-Q
Revenue$5.00K$5.00K−86.8% vs Q1 2015 Net Income-$133.63K-$133.63KN/M vs Q1 2015 EPS Diluted-$0.01-$0.01N/M vs Q1 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Margins · derivedGross margin100.0%+54.1 pt vs Q1 2015
Net margin-2672.5%−965.4 pt vs Q1 2015
ended Mar 31, 2016 · filed Aug 7, 2017 · 494 d after period end